Reversal of p-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative

British Journal of Cancer

Volumn 78, Issue 7, 1998, Pages 885-892

  Dale, I L ^a   Tuffley, W ^a   Callaghan, R ^b   Holmes, J A ^c   Martin, K ^a   Luscombe, M ^a   Mistry, P ^a   Ryder, H ^a   Stewart, A J ^a   Charlton, P ^a   Twentyman, P R ^c   Bevan, P ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Diketopiperazine; Multidrug resistance; P glycoprotein; Resistance modifying agent; XR9051

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; METHOTREXATE; PIPERAZINEDIONE; VERAPAMIL; VINCRISTINE;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG BINDING; DRUG INTERACTION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 7344267995     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.597     Document Type: Article

References (28)

1. Barrand MA, Rhodes T, Center MS and Twentyman PR (1992) Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190 k membrane protein distinct from P-glycoprotein. Eur J Cancer 29A: 408-415
2. Boesch D and Loor F (1994) Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anticancer Drugs 5: 229-238
3. Boesch D, Gaveraux C, Jachez B, Pourtier-Manzanedo A, Bollinger P and Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumour cells with SDZ PSC 833. Cancer Res 51: 4226-4233
4. Callaghan R, Berridge G, Ferry DR and Higgins CF (1997) The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. Biochim Biophys Acta 1328: 109-124
5. Dantzig AH, Shepard RL, Cao J, Law KL, Ehldardt WJ, Baughman TM, Bumol TF and Starling JJ (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171-4179
6. De Lean A, Munson PJ, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: applications to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235: E97-E102
7. 3H]azidopine. FEBS Lett 169: 112-118
8. Ferry DR, Russel MA and Cullen MH (1992) P-glycoprotein possesses a 1,4-dihydropyridine selective drug acceptor site which is allosterically coupled to a vinca alkaloid selective binding site. Biochem Biophys Res Commun 188: 440-445
9. Ford JM (1996). Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A: 991-1001
10. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J and Harding MW (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8: 125-140
11. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427
12. Greenberger LM, Williams SS, Georges E, Ling V and Horwitz SB (1988) Electrophoretic analysis of P-glycoproteins produced by mouse J774.2 and chinese hamster ovary multidrug resistant cells. J Natl Cancer Inst 80: 506-510
13. Hyafil F, Vergely C, Du Vignaud P and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resitance by GF120918, an acridone carboxamide derivative. Cancer Res 53: 4595-4602
14. Johnson RK, Chitnis MP, Embrey WM and Gregory EB (1978) In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukaemia. Cancer Treat Rep 62: 1535-1547
15. Kartner N, Riordan JR, and Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285-1288
16. Lever JE (1977) Active amino-acid transport in plasma membrane vesicles from Simian virus 40-transformed mouse fibroblasts. Characteristics of electrochemical Na+ gradient stimulated uptake. J Biol Chem 252: 1990-1997
17. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J and Sikic BI (1993) Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72 (suppl): 3502-3514
18. Pierré A, Dunn TA, Kraus-Berthier L, Léonce S, Saint-Dizier D, Regnier G, Dhainaut A, Berlion M, Bizzari JP, Atassi G (1992) In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs 10: 137-148
19. Raderer M and Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. Cancer 72: 3553-3563
20. Rogan AM, Hamilton TC, Young RC, Klecker RW and Ozols RF (1984) Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996
21. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM, Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Invest 96: 1698-1705
22. Simon SM and Schindler M (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91: 3497-3504
23. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
24. Spoelstra EC, Westerhoff HV, Pinedo HM, Dekker H and Lankelma J (1994) The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur J Biochem 221: 363-373
25. Twentyman PR, Fox NE, Wright KA and Bleehen NM (1986) Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer 53: 529-537
26. Twentyman PR, Reeve JG, Koch G and Wright KA (1990) Chemosensitization by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin). Br J Cancer 62: 89-95
27. Yang CP, Mellado W and Horwitz SB (1988) Azidopine photoaffinity labeling of multidrug resistance-associated glycoproteins. Biochem Pharmacol 37: 1417-1421
28. Zhou D-C, Simonin G, Faussat A-M, Zittou R, Marie J-P (1997) Effect of the multidrug inhibitor GG918 on drug sensitivity of leukemic cells. Leukemia 11: 1516-1522